English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, July 8, 2022
中國抗體獲香港科學園最高專項補貼
Tuesday, June 21, 2022
中国抗体的旗舰产品舒西利单抗SM03的作用机理在美国免疫领域权威期刊the Journal of Immunology上成功发表
中國抗體的旗艦產品舒西利單抗SM03的作用機理在美國免疫領域權威期刊the Journal of Immunology上成功發表
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.
Wednesday, June 15, 2022
中国抗体在美国完成SM17 I期临床试验首例健康受试者给药
中國抗體在美國完成SM17 I期臨床試驗首例健康受試者給藥
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.
Thursday, June 9, 2022
中国抗体公布SN1011新药研究申请获中国国家药品监督管理局药品审评中心受理
中國抗體公佈SN1011新藥研究申請獲中國國家藥品監督管理局藥品審評中心受理
SinoMab Announces IND Application for SN1011 Accepted by NMPA CDE

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575